Affordable Access

Publisher Website

siRNA nanotherapeutics: a Trojan horse approach against HIV

Authors
Journal
Drug Discovery Today
1359-6446
Publisher
Elsevier
Identifiers
DOI: 10.1016/j.drudis.2014.09.019
Disciplines
  • Medicine

Abstract

The concept of RNA interference (RNAi) is gaining popularity for the better management of various diseases, including HIV. Currently, the successful biomedical utilization of siRNA therapeutics is hampered, both in vivo and in vitro, mainly by the inherent inability of naked siRNA to cross the cell membrane. RNAi can potentially improve the weakness of current highly active antiretroviral therapy (HAART) by diminishing the chances of the appearance of antiHIV-resistant strains. Here, we discuss the nanocarrier-mediated delivery of siRNA delivery as well as highlighted the scope of siRNA-mediated gene-silencing technology for improved HIV treatment.

There are no comments yet on this publication. Be the first to share your thoughts.